儿童癌症治疗对卵巢储备激素及超声标志物的长期影响
荷兰全国性回顾性队列研究纳入564例女性儿童癌症生存者(CCS)和390例对照,发现环磷酰胺、丙卡巴肼、其他烷化剂组、放线菌素D、多柔比星、米托蒽醌、脊柱放疗、腹/盆腔放疗和全身照射与至少一项卵巢储备标志物异常多变量相关,丙卡巴肼和腹/盆腔放疗存在剂量效应关系。
要点
- 35岁以上CCS异常卵巢储备标志物比例显著高于对照:AMH 26% vs 4%,AFC 20% vs 3%,抑制素B 42% vs 16%。
- 环磷酰胺、丙卡巴肼、其他烷化剂组、放线菌素D、多柔比星、米托蒽醌、脊柱放疗、腹/盆腔放疗和全身照射与至少一项卵巢储备标志物异常多变量相关。
- 丙卡巴肼和腹/盆腔放疗与卵巢储备标志物异常存在剂量效应关系。
核心结论
- 大多数儿童癌症生存者未显示卵巢储备降低的迹象,但特定亚组与高风险相关。
- 研究结果对儿童癌症生存者及未来患者关于生育和生育力保存的咨询具有重要意义。
研究设计与样本
- DCOG LATER-VEVO为全国性回顾性队列研究,测量于2008年至2014年间进行。
- 邀请1749例1963年至2002年间诊断、诊断时年龄小于18岁的女性5年癌症生存者和1201例对照参与研究。
- 研究为多中心研究,包括所有七家荷兰儿童肿瘤/血液学中心。
- 卵巢储备通过抗苗勒管激素(AMH)、促卵泡激素(FSH)、抑制素B水平和窦卵泡计数(AFC)评估。
- 564例癌症生存者和390例对照参与研究的临床部分。
主要发现
- 总体而言,7.0-17.7%的癌症生存者和2.4-13.6%的对照具有异常的卵巢储备标志物。
- 35岁以上,癌症生存者较对照有显著更多异常卵巢储备标志物:AMH 26% vs 4%;AFC 20% vs 3%;抑制素B 42% vs 16%。
- 对于AMH和FSH,在35岁以下也发现显著差异。
- 环磷酰胺、丙卡巴肼、一组「其他烷化剂」、放线菌素D、多柔比星、米托蒽醌、脊柱放疗、腹/盆腔放疗和全身照射与至少一项卵巢储备标志物异常多变量相关。
- 丙卡巴肼和腹/盆腔放疗存在剂量效应关系。
临床怎么用
- 作者认为,研究结果对儿童癌症生存者及未来患者关于生育和生育力保存的咨询具有重要意义。
局限性
- 尽管研究规模大,但由于特定分析参与人数有限,无法对所有治疗类型研究剂量效应关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Which treatment-related factors are (dose-dependently) associated with abnormal hormonal and ultrasound markers of ovarian reserve in female childhood cancer survivors (CCSs)? SUMMARY ANSWER: Cyclophosphamide, procarbazine, a composite group of 'other alkylating agents', dactinomycin, doxorubicin, mitoxantrone, spinal radiotherapy (RT), abdominal/pelvic RT and total body irradiation were multivariably associated with abnormal ovarian reserve markers, with dose-effect relationships being established for procarbazine and abdominal/pelvic RT. WHAT IS KNOWN ALREADY: Female childhood cancer survivors are at an increased risk of reduced ovarian function and reserve, but knowledge regarding the long-term effects of individual chemotherapeutic (CT) agents and radiotherapy fields and their respective doses is limited. STUDY DESIGN, SIZE, DURATION: The DCOG LATER-VEVO is a nationwide retrospective cohort study in which measurements were performed between 2008 and 2014. In total, 1749 female 5-year CCSs, diagnosed before age 18 years between 1963 and 2002 and 1201 controls were invited for the study. PARTICIPANTS/MATERIALS, SETTING, METHODS: Ovarian reserve was assessed by anti-Müllerian hormone (AMH), follicle stimulating hormone (FSH), inhibin B levels, and antral follicle counts (AFC). The study was a multicentre study including all seven Dutch Centers for Paediatric Oncology/Haematology. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 564 CCs and 390 controls participated in the clinical part of the study. Overall, 7.0-17.7% of CCSs and 2.4-13.6% of controls had abnormal ovarian reserve markers. Above age 35, significantly more CCSs than controls had abnormal ovarian reserve markers (AMH: 26% vs. 4%; AFC: 20% vs. 3%; inhibin B: 42% vs. 16%). For AMH and FSH, significant differences were also found below age 35. Cyclophosphamide, procarbazine, a group of 'other alkylating agents', dactinomycin, doxorubicin, mitoxantrone, spinal RT, abdominal/pelvic RT and total body irradiation were multivariably associated with at least one abnormal ovarian reserve marker. Dose-effect relationships were established for procarbazine and abdominal/pelvic RT. LIMITATIONS, REASONS FOR CAUTION: Despite the large scale of the study, dose-effect relationships could not be investigated for all types of treatment due to a limited numbers of participants for specific analyses. WIDER IMPLICATIONS OF THE FINDINGS: This study demonstrated that the majority of CCSs do not show signs of a reduced ovarian reserve. However, specific subgroups of CCSs appear to be associated with a high risk. Our results are important for counselling CCSs and future patients regarding parenthood and fertility preservation. STUDY FUNDING/COMPETING INTERESTS: This study was funded by the Dutch Cancer Society (Grant no. VU 2006-3622) and by the Children Cancer Free Foundation (Project no. 20). Philips Health Systems Benelux supported this study by providing three ultrasound systems and concomitant analytic software. There are no competing interests. TRIAL REGISTRATION NUMBER: NTR2922 http://www.trialregister.nl/trialreg/admin/rctview.asp?TC = 2922.
引用
- van den Berg MH, Overbeek A, Lambalk CB, et al. Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve. Hum Reprod. 2018. PMID: 29982673. doi:10.1093/humrep/dey229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。